

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

Please cancel claims 13-40, 47-62, 64-65, 67-76 and 78-81 without prejudice or disclaimer.

**Listing of Claims:**

1. (Original) A method for treating an inflammatory disease or reducing an inflammatory reaction, said method comprising: administering a SOC inhibitor, thereby treating said inflammatory disease or reducing said inflammatory reaction.
2. (Original) The method of claim 1, wherein said inflammatory disease or inflammatory reaction is a skin disorder.
3. (Original) The method of claim 2, wherein said skin disorder is selected from the group consisting of atopic dermatitis, psoriasis, neurogenic inflammation, skin photodamage, a cell carcinoma, keratosis, and a disorder of keratinization.
4. (Original) The method of claim 1, wherein said inflammatory disease or inflammatory reaction is an inflammatory pulmonary disease or reaction.
5. (Original) The method of claim 4, wherein said inflammatory pulmonary disease or reaction is selected from the group consisting of asthma, allergic rhinitis, chronic obstructive pulmonary disease and adult respiratory distress syndrome.
6. (Original) The method of claim 1, wherein said inflammatory disease or inflammatory reaction is an inflammatory musculoskeletal disease or reaction.
7. (Original) The method of claim 6, wherein said inflammatory musculoskeletal disease is a member selected from the group consisting of psoriatic arthritis, osteoarthritis, and osteoporosis.
8. (Original) The method of claim 1, wherein said inflammatory disease or inflammatory reaction is an inflammatory gastrointestinal or urogenital disease or reaction.

9. (Original) The method of claim 8, wherein said inflammatory gastrointestinal or urogenital disease or reaction is a member selected from the group consisting of inflammatory bowel disease, enterocolitis, gastritis, vaginitis, and interstitial cystitis.


10. (Original) The method of claim 1, wherein said inflammatory disease or inflammatory reaction is an autoimmune disease or reaction.

11. (Original) The method of claim 10, wherein said autoimmune disease is a member selected from the group consisting of multiple sclerosis, type II diabetes, lupus, and rheumatoid arthritis.

12. (Original) The method of claim 1, wherein said inflammatory disease or inflammatory reaction is transplantation treatment.

13 - 40. (Canceled).

41. (Original) A compound having the formula



wherein:


R<sup>1</sup> is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

R<sup>2</sup> is independently a member selected from the group consisting of optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^8$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^9$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively,  $R^8$  and  $R^9$  and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring.

42. (Original) The compound of claim 41, wherein said compound is a member selected from the group consisting of





wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted ( $C_2$ - $C_{18}$ )alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkoxy, and optionally substituted; and

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy.

43. The compound of claim 42, wherein  $R^1$  is a member selected from the group consisting of






to about 14 and  $\text{---}(\text{CH}=\text{CH})_3\text{---R}^3$ ; and  $\text{---}(\text{CH}=\text{CH})_2\text{---}(\text{CH}_2)_x\text{---R}^3$  wherein x is about 1

R<sup>3</sup> is a member selected from the group consisting of consisting of alkyl, alkoxy sulfonyl, dialkylphosphono, optionally substituted carbamoyl, alkylthiocarbonyl, optionally substituted alkylamido, optionally substituted amidino, optionally substituted alkylsulfonamido, alkoyloxyamino, alkylaminosulfonamido, and alkoxy carbonyl.

[illegible]

45. (Original) The compound of claim 42, wherein R<sup>2</sup> is a member selected from the group consisting of consisting of




46. (Original) The compound of claim 45, wherein  $R^2$  is p-fluorophenyl.

47 - 62. (Canceled)

63. (Original) A pharmaceutical composition, said pharmaceutical composition comprising:

a compound having the formula



wherein:

$R^1$  is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroarylminooxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

$R^2$  is independently a member selected from the group consisting of optionally substituted ( $C_1$ - $C_6$ )alkyl, optionally substituted ( $C_1$ - $C_6$ )alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^8$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

$R^9$  is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted

heteroarylalkyl, optionally substituted heteroarylalkoxy; or alternatively, R<sup>8</sup> and R<sup>9</sup> and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring; and  
a pharmaceutically acceptable excipient therefor.


64. (Canceled)

65. (Canceled)

66. (Original) A method for blocking calcium influx from the extracellular space, said method comprising: contacting a cell with a store operated calcium influx (SOC) inhibitor, thereby blocking calcium influx from the extracellular space.

67 - 76. (Canceled)

77. (Original) The method of claim 66, wherein said SOC inhibitor is a compound having the formula



wherein:

R<sup>1</sup> is a member selected from the group consisting of optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylene having at least 2 sites of unsaturation, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylthioalkyl, optionally substituted heteroaryliminoxyalkyl, optionally substituted heterocyclyl, optionally substituted oximinoaryl and optionally substituted heteroarylalkoxy;

R<sup>2</sup> is independently a member selected from the group consisting of optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally substituted (C<sub>1</sub>-C<sub>6</sub>)alkoxy, acyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

R<sup>8</sup> is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy;

R<sup>9</sup> is a member selected from the group consisting of an optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, and optionally substituted heteroarylalkoxy; or alternatively, R<sup>8</sup> and R<sup>9</sup> and the carbons to which they are attached, joined to form an optionally substituted aryl or optionally substituted heteroalkyl 5-or 6 membered ring.

78 - 81. (Canceled)

82. (Original) A method for treating inflammatory bowel disease (IBD), said method comprising:

administering a store operated calcium influx (SOC) inhibitor, thereby treating inflammatory bowel disease (IBD).

83. (Original) A method of treating a disease, comprising administering a pharmaceutical composition comprising an aerosol formulation of a SOC inhibitor, wherein said disease is selected from the group consisting of acute lung injury, adult respiratory distress syndrome, asthma, interstitial lung disease, emphysema, chronic bronchitis and cystic fibrosis.